Left ventricular mass on positron emission tomography: Validation against cardiovascular magnetic resonance
- PMID: 33629247
- DOI: 10.1007/s12350-021-02537-6
Left ventricular mass on positron emission tomography: Validation against cardiovascular magnetic resonance
Abstract
Background: Left ventricular hypertrophy (LVH) is an important clinical finding that is independently associated with mortality and cardiovascular events. We aimed to assess the interstudy variability of LV mass quantitation between PET and CMR.
Methods: Patients who underwent both PET and CMR within 1 year were identified from prospective institutional registries. LV mass on PET was compared against LV mass on CMR using several statistical measures of agreement.
Results: A total of 105 patients (mean age 60 ± 14 years, 67.6% male) were included. The median (interquartile range, IQR) duration between CMR and PET was 47 (11-154) days. The median (IQR) LV mass values were 168.0 g (126.0-202.0) on CMR and 174.0 g (150.0-212.0) with PET (absolute mean difference 29.42 ± 25.3). There was a good correlation (Spearman ρ = 0.81, P < 0.001; Intraclass Correlation Coefficient 0.78, 95% CI 0.70-0.85, P < 0.001) with moderate limits of agreement (95% limits of agreement - 63.78 to 83.7.) Results were consistent, albeit with moderate correlation, in subgroups of patients with LVH, in patients with myocardial infarction, in patients with LV ejection fraction < 50%, and those with limited image quality. LV mass on PET tended to be underestimated at high values compared to CMR.
Conclusion: We demonstrate good correlation and reproducibility of LV mass quantitation by PET against the reference standard of CMR across a wide range of normal and diseased hearts with a tendency of PET to underestimate mass at higher mass values.
Keywords: CMR; PET; nuclear cardiac imaging.
© 2021. American Society of Nuclear Cardiology.
Comment in
-
82Rb PET/CT left ventricular mass computations.J Nucl Cardiol. 2022 Aug;29(4):1643-1646. doi: 10.1007/s12350-021-02593-y. Epub 2021 Mar 21. J Nucl Cardiol. 2022. PMID: 33748939 No abstract available.
References
-
- Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med 1990;322:1561-6. - DOI
-
- Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998;32:1454-9. - DOI
-
- Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9. - DOI
-
- Cianciulli TF, Saccheri MC, Masoli OH, et al. Myocardial perfusion SPECT in the diagnosis of apical hypertrophic cardiomyopathy. J Nucl Cardiol 2009;16:391-5. - DOI
-
- Farber NJ, Reddy ST, Doyle M, et al. Ex vivo cardiovascular magnetic resonance measurements of right and left ventricular mass compared with direct mass measurement in excised hearts after transplantation: A first human SSFP comparison. J Cardiovasc Magn Reson 2014;16:74. - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
